Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells
Fig 5
Rapamycin enhanced the inhibiting effect of Dasatinib on invasion and migration in A549 cells.
(A) Representative images (upper panel) and quantification (lower panel) of invading cells. As detailed by “cell invasion assay” in the “Methods”, A549 cells were treated with DMSO (0.1%), Dasatinib (10 nM) alone or in combination with Rapamycin (100 nM) for 24 h. The numbers of invading cells were counted under microscope and the data was presented as mean ± SD from three independent experiments, * p < 0.05, ** p < 0.01. (B) Representative images of wound healing assays in A549 cells that were treated with DMSO (0.1%), Dasatinib (10 nM) or Rapamycin (100 nM) for 18 h. (C) The expression of MMP-2/9 and E-cadherin determined by western blotting in A549 cells that were treated with DMSO (0.1%), Dasatinib (10 nM) or Rapamycin (100 nM) for 24 h.